Gastroenterology

The cut points for LCT and nCD64 in Crohn’s disease were not previously known.

Fecal material transplantation for the management of patients with IBD demonstrates a response rate of 53.8% with a complete remission of 37%.

This article is the third in a series of four articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.

Ustekinumab should be prescribed cautiously to those at high cardiovascular risk.

Low levels of COC associated with a higher likelihood of outpatient flares that required corticosteroids, hospitalizations, and surgical interventions.

There are currently no FDA-approved treatments for eosinophilic esophagitis.

This article is the second in a series of four articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.

This article is the first in a series of 4 articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.

In a poster presented at ERS, researchers find the complement and coagulation cascades pathway was up-regulated in response to airway presence of Moraxella genera that might suggest an activation of systemic innate immunity in response to Moraxella.

There was no differences found between liver transplant patients and a control group on the proportion of hospitalized patients and patients who required intensive care.

No life-threatening adverse events occurred in the 150 patient trial to treat non-alcoholic fatty liver disease.

A sibling control group showed similar results as a general population control group.

A gastroenterologist discusses how gastrointestinal symptoms are manifesting in patients with COVID-19.

Dr. Erica Brenner talks about how gastroenterologists should safely return to screening and diagnosing patients.

An expert discusses how a registry of gastrointestinal symptoms is leading research during COVID-19.

A gastroenterologist discusses some of the findings regarding COVID-19 and gastrointestinal symptoms.

Firmicutes bacteria can help produce metabolites that maintain intestinal barriers and mucosal immunity.

There is a higher prevalence of IBS found in women than men.

Nearly two-thirds of COVID-19 patients have gastrointestinal symptoms.

The expansion makes history for the injection biologic.

The association of DAA treatment with mortality did not differ by sex in the cirrhosis group.

New scoring model is based on an eight-point threshold to accurately predict patients at a low risk of adverse outcomes.

The 8-7 decision allows Mallinckrodt to move forward with a Sept. 12 PDUFA date for the investigational agent.

Patients in the multidisciplinary-care group were more likely to experience a 50% or higher reduction in all Gastrointestinal Symptom Severity Index symptom clusters than the patients who were in the standard-care group.

In a sample of patients treated with laparoscopic ileocecal resection, 42% (n = 29) of patients did not require additional Crohn’s disease-related medication, while 48% (n = 14) were given prophylactic immunomodulator therapy.